Neutralizing interleukin-1β suppressed post-MI hematopoietic stem cell proliferation, decreased leukocyte numbers, reduced inflammation, and diminished heart failure in ApoE(-/-) mice.
BACKGROUND: Myocardial infarction (MI) is an ischemic wound that recruits millions of leukocytes. MI-associated blood leukocytosis correlates inversely with patient survival, yet the signals driving heightened leukocyte production after MI remain incompletely understood. METHODS AND RESULTS: With the use of parabiosis surgery, this study shows that soluble danger signals, among them interleukin-1β, increase bone marrow hematopoietic stem cell proliferation after MI. Data obtained in bone marrow reconstitution experiments reveal that interleukin-1β enhances hematopoietic stem cell proliferation by both direct actions on hematopoietic cells and through modulation of the bone marrow's hematopoietic microenvironment. An antibody that neutralizes interleukin-1β suppresses these effects. Anti-interleukin-1β treatment dampens the post-MI increase in hematopoietic stem cell proliferation. Consequently, decreased leukocyte numbers in the blood and infarct reduce inflammation and diminish post-MI heart failure in ApoE(-/-) mice with atherosclerosis. CONCLUSIONS: The presented insight into post-MI bone marrow activation identifies a mechanistic target for muting inflammation in the ischemically damaged heart.
Sager et al. (Fri,) conducted a other in Acute Myocardial Infarction. Anti-interleukin-1β antibody was evaluated on Bone marrow hematopoietic stem cell proliferation, leukocyte numbers, and post-MI heart failure. Neutralizing interleukin-1β suppressed post-MI hematopoietic stem cell proliferation, decreased leukocyte numbers, reduced inflammation, and diminished heart failure in ApoE(-/-) mice.